drug development

News

New draft guidance from the FDA is urging pharma companies to accelerate efforts to transition from animal testing to non-animal alternatives.

R&D

Biotechs and pharmaceutical companies can receive enormous value from a trusted partnership with an integrated CDMO and CRO.

R&D

Find out more about Senior Director of CMC Portfolio Management, Thermo Fisher Scientific, Trenton M. Johnson in a new 12 Questions With.

Sales & Marketing

Thermo Fisher Scientific’s Accelerator Drug Development is a suite of integrated services combining CDMO and CRO to streamline drug development.

Digital

Digital